L-α-lysophosphatidylinositol meets GPR55: a deadly relationship.

Abstract

Evidence points to a role of L-α-lysophosphatidylinositol (LPI) in cancer. First, clinical data identified LPI as a biomarker for poor prognosis in cancer patients. Second, in vitro studies demonstrated significantly elevated levels of LPI in highly proliferative cancer cells. Third, LPI displays mitogenic activity in cancer cell lines, in which the lipid significantly increased cell proliferation. However, a receptor target for LPI remained elusive until very recently. It has now been revealed that LPI activates GPR55, a G protein-coupled receptor that couples to G(12/13) and G(q) proteins, which direct oncogenic signalling. New evidence indicates that LPI and GPR55 are key partners in driving cancer cell proliferation and migration. GPR55 is expressed in human tumours and drives proliferation and its expression correlates with tumour aggressiveness. Overall patient survival is lower in patients whose glioblastomas express higher levels of GPR55. Thus, evidence suggests that interaction with GPR55 might underlie the pro-tumoural actions of LPI.

• Authors: Ruth A Ross
• Journal: Trends in pharmacological sciences (Trends Pharmacol Sci) Vol. 32 Issue 5 Pg. 265-9 (May 2011) ISSN: 1873-3735 [Electronic] England
• PMID: 21367464 (Publication Type: Journal Article)
• Copyright: Copyright © 2011 Elsevier Ltd. All rights reserved.

Chemical References

• Biomarkers, Tumor
• GPR55 protein, human
• Lysophospholipids
• Receptors, Cannabinoid
• Receptors, G-Protein-Coupled
• lysophosphatidylinositol

Topics

• Animals
• Biomarkers, Tumor (metabolism)
• Cell Movement
• Cell Proliferation
• Glioblastoma (physiopathology)
• Humans
• Lysophospholipids (metabolism)
• Neoplasms (physiopathology)
• Receptors, Cannabinoid
• Receptors, G-Protein-Coupled (metabolism)
• Survival